Company research
Cuprina Holdings (Cayman) LTD
CIK 1995704Updated Oct 6, 2026
SecurityCUPR · NASDAQ · equity
CUPR price & chart
Loading TradingView…
NASDAQ:CUPR on TradingView ↗About the company
We are a Singapore-based biomedical and biotechnology company that is dedicated to the development and commercialization of innovative products for the management of chronic wounds, as well as operating in the health and beauty sector. Our expertise in biomedical research allows us to identify and utilize materials derived from natural sources to develop wound care products in the form of medical devices which meet international standards. We believe we will be able to build upon and leverage such expertise to develop innovative cosmeceutical products in the future.
In the news
Recent filings
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|
| ASSETS | |||
| AssetsUSD | 6,611,675Source | 1,282,831Source | 1,585,701Source |
| Property, Plant and Equipment, NetUSD | 60,270Source | 42,685Source | 78,366Source |
| Current assets: | |||
| Cash and Cash Equivalents, at Carrying ValueUSD | 2,423,760Source | 85,622Source | 35,263Source |
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | 14,163Source | 19,399Source | 50,819Source |
| Inventory, NetUSD | — | 1,272Source | 7,665Source |
| Assets, CurrentUSD | 5,699,428Source | 1,217,401Source | 1,435,049Source |
| Prepaid Expense and Other Assets, CurrentUSD | 3,006,492Source | 58,610Source | 72,603Source |
| Operating Lease, Right-of-Use AssetUSD | 246,229Source | 22,745Source | 72,286Source |
| Other Assets, NoncurrentUSD | 605,748Source | — | — |
| LIABILITIES AND EQUITY | |||
| LiabilitiesUSD | 2,681,467Source | 4,561,315Source | 4,482,985Source |
| Stockholders’ equity: | |||
| Additional Paid in CapitalUSD | 10,816,122Source | 57,871Source | 78,722Source |
| Retained Earnings (Accumulated Deficit)USD | -7,179,118Source | -3,352,976Source | -3,000,518Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | 271,115Source | -1,172Source | 309Source |
| Stockholders' Equity Attributable to ParentUSD | 3,930,208Source | -3,278,484Source | -3,278,484Source |
| Liabilities and EquityUSD | 6,611,675Source | 1,282,831Source | 1,585,701Source |
| Current liabilities: | |||
| Liabilities, CurrentUSD | 2,421,996Source | 4,440,953Source | 4,425,473Source |
| Operating Lease, Liability, CurrentUSD | 85,698Source | 26,327Source | 43,458Source |
| Accounts Payable, CurrentUSD | 915Source | — | — |
| Operating Lease, Liability, NoncurrentUSD | 161,359Source | — | 35,812Source |
| Additional Financial Items | |||
| Accrued Liabilities, CurrentUSD | 23,809Source | 238,161Source | 375,439Source |
| Long-term Debt, Excluding Current Maturities | — | — | — |
| Long-term Debt, Current MaturitiesUSD | 30,108Source | 40,616Source | — |
| Long-term Debt, Excluding Current MaturitiesUSD | 98,112Source | 120,362Source | — |
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|
| Cash flows from operating activities: | |||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | -3,633,248Source | -1,147,199Source | -1,119,555Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | |||
| Depreciation and amortization | — | — | — |
| Changes in operating assets and liabilities: | |||
| Increase (Decrease) in Accounts ReceivableUSD | -6,337Source | -17,959Source | 37,511Source |
| Increase (Decrease) in InventoriesSGD | — | — | 1,164Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | -7,100,947Source | -908,609Source | -894,981Source |
| Cash flows from investing activities: | |||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | -45,268Source | -16,088Source | -67,977Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | 45,268Source | 16,088Source | 67,977Source |
| Cash flows from financing activities: | |||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | 9,509,245Source | 985,795Source | 433,075Source |
| Supplemental disclosure of cash flow information: | |||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | 54,874Source | 162Source | 727Source |
| Additional Financial Items | |||
| DepreciationUSD | 28,394Source | 31,012Source | 42,185Source |
| Equity Method Investment, Realized Gain (Loss) on DisposalUSD | -49,249Source | -38,176Source | -33,788Source |
| Foreign Currency Transaction Gain (Loss), before TaxUSD | -109,782Source | 1,280Source | -2,484Source |
| Gain (Loss) on Disposition of Property Plant EquipmentUSD | -1,746Source | — | — |
| Inventory Write-downUSD | 1,345Source | 4,363Source | — |
| Net Income (Loss) Attributable to ParentUSD | -3,633,248Source | -1,147,199Source | -1,119,555Source |
| Nonoperating Income (Expense)USD | 170,824Source | 100,459Source | -17,438Source |
| Operating ExpensesUSD | 3,754,322Source | 1,207,259Source | 1,104,934Source |
| Other Operating Income (Expense), NetUSD | 182,271Source | 127,813Source | 39,149Source |
| Payments of Financing CostsUSD | 2,043,647Source | 311,539Source | 647,796Source |
| Proceeds from Issuance of Common StockUSD | 13,687,351Source | — | — |
| Provision for Loan, Lease, and Other LossesUSD | -2,960Source | -1,553Source | 106Source |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|
| Total RevenueUSD | 38,789Source | 35,522Source | 100,773Source |
| Cost of Goods and Services Sold | — | — | — |
| Selling, General and Administrative ExpenseUSD | 3,577,937Source | 1,029,826Source | 937,200Source |
| Operating Income (Loss)USD | -3,754,823Source | -1,209,482Source | -1,068,329Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | -3,583,999Source | -1,109,023Source | -1,085,767Source |
| Net Income (Loss) Attributable to ParentUSD | -3,633,248Source | -1,147,199Source | -1,119,555Source |
| Earnings Per Share, BasicUSD per share | -17.75Source | -6.38Source | -6.22Source |
| Earnings Per Share, DilutedUSD per share | -17.75Source | -6.38Source | -6.22Source |
| Weighted Average Number of Shares Outstanding, Basicshares | 20,471,507Source | 18,000,000Source | 18,000,000Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 20,471,507Source | 18,000,000Source | 18,000,000Source |
| Additional Financial Items | |||
| Depreciation, Depletion and Amortization, NonproductionUSD | 28,394Source | 31,012Source | 35,059Source |
| Foreign Currency Transaction Gain (Loss), before TaxUSD | -109,782Source | 1,280Source | -2,484Source |
| Gross ProfitUSD | -501Source | -2,223Source | 36,605Source |
| Interest and Other IncomeUSD | 20,650Source | — | — |
| Interest ExpenseUSD | 11,447Source | 1,311Source | 727Source |
| Interest Income (Expense), NetUSD | -11,447Source | -27,354Source | -56,587Source |
| Nonoperating Income (Expense)USD | 170,824Source | 100,459Source | -17,438Source |
| Operating ExpensesUSD | 3,754,322Source | 1,207,259Source | 1,104,934Source |
| Other Operating Income (Expense), NetUSD | 182,271Source | 127,813Source | 39,149Source |
| Research and Development ExpenseUSD | 176,385Source | 177,433Source | 177,433Source |
Offerings
Registration 333-297299
- Net proceeds
- 5316337.0
- Deal price
- 1.15
- Offering amount
- $2.93.
- Offering price
- $1.15
- Ticker
- CUPR
Underwriters: R.F. Lafferty & Co., Inc.
Filing attachments
ex99-1.htm · 6-K · 2026-10-02
Exhibit 99.1 Cuprina (Nasdaq: CUPR) to Acquire EBITDA-Positive Seven-Clinic Singapore Healthcare Group (i) Acquiring 100% of East Coast Podiatry (five clinics) and Orchard Clinic (two clinics) for approximately S$4.0 million (approximately US$3.1 million) (ii) Target Group generated FY2025 unaudited revenue of approximately S$9.1 million and unaudited normalized EBITDA of approximately S$1.2 million, based on unaudited management accounts (iii) Sellers’ consideration shares subject to a lock…
Read attachment ↗ex99-1.htm · 6-K · 2026-09-29
Exhibit 99.1 Cuprina Holdings (Cayman) Limited Announces Closing of Underwriter’s Over-Allotment Option in Connection with Public Offering SINGAPORE, September 29, 2026 - Cuprina Holdings (Cayman) Limited ( Nasdaq: CUPR ) (“ Cuprina ” or “ the Company ”), a biomedical company developing and marketing products for the chronic wounds, infertility, medical waste recycling, and cosmeceuticals sectors, today announced that it closed the sale of an additional 648,373 Class A ordinary shares of the …
Read attachment ↗ex99-1.htm · 6-K · 2026-09-18
Exhibit 99.1 Cuprina Holdings (Cayman) Limited (Incorporated in the Cayman Islands with limited liability) Notice of Extraordinary General Meeting of Shareholders To Be Held on October 15, 2026, at 9:00 p.m., local time NOTICE IS HEREBY GIVEN THAT the extraordinary general meeting (the “ Meeting ” or “ EGM ”) of the shareholders of Cuprina Holdings (Cayman) Limited (the “ Company ”) will be held at Blk 1090 Lower Delta Road #06-10, Singapore 169201, and via live webcast, on October 15, 2026…
Read attachment ↗ex4-1.htm · 6-K · 2026-09-18
Exhibit 4.1 REPRESENTATIVE ORDINARY SHARE PURCHASE WARRANT Cuprina Holdings (Cayman) Limited Issue Date: September 17, 2026 ────────────────────────────────────────────────────────── Warrant Shares: 172,900 Initial Exercise Date: March 17, 2027 THIS REPRESENTATIVE ORDINARY SHARE PURCHASE WARRANT (the “ Warrant ”) certifies that, for value received, R.F. Lafferty & Co., Inc. or its assigns (th…
Read attachment ↗ex99-1.htm · 6-K · 2026-09-18
Exhibit 99.1 Cuprina Holdings (Cayman) Limited Announces Pricing of $4.97 million Public Offering SINGAPORE, September 16, 2026 - Cuprina Holdings (Cayman) Limited ( Nasdaq: CUPR ) (“ Cuprina ” or “ the Company ”), a biomedical company developing and marketing products for the chronic wounds, infertility, medical waste recycling, and cosmeceuticals sectors, today announced the pricing of its firm commitment public offering of an aggregate 4,322,489 shares of its Class A Ordinary Shares (“ the …
Read attachment ↗